NASDAQ:NRSN
NeuroSense Therapeutics Ltd.
- Stock
Last Close
0.76
30/08 20:00
Market Cap
17.50M
Beta: -
Volume Today
1.35M
Avg: 65.36K
PE Ratio
−1.38
PFCF: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | -89K - | -1.93M 2,066.29% | -1.84M 4.62% | |||
average payables | 39K - | 47K 20.51% | 268.50K 471.28% | 978.50K 264.43% | ||
average receivables | 24K - | 104K 333.33% | 154.50K 48.56% | 148.50K 3.88% | ||
book value per share | 0.08 - | 0.06 28.21% | 1.44 2,295.42% | 0.49 66.14% | -0.14 128.13% | |
capex per share | -0.00 - | -0.00 28.57% | -0.00 231.09% | -0.01 123.46% | -0.00 65.06% | |
capex to depreciation | -3 - | -5.67 88.89% | -0.79 86.12% | -0.30 61.99% | ||
capex to operating cash flow | 0.01 - | 0.01 7.67% | 0.01 14.70% | 0.01 16.46% | 0.00 62.02% | |
capex to revenue | ||||||
cash per share | 0.08 - | 0.06 21.90% | 1.77 2,674.16% | 0.62 65.22% | 0.20 68.12% | |
days of inventory on hand | ||||||
days payables outstanding | 5.49K - | |||||
days sales outstanding | ||||||
debt to assets | 0.03 - | 0.04 63.37% | ||||
debt to equity | 0.04 - | -0.08 301.79% | ||||
dividend yield | ||||||
earnings yield | -0.03 - | -0.06 130.56% | -0.16 153.87% | -0.80 391.09% | -1.05 32.05% | |
enterprise value | 43.32M - | 43.51M 0.45% | 4.30M 90.13% | 10.70M 149.16% | 8.17M 23.67% | |
enterprise value over ebitda | -34.57 - | -15.41 55.43% | -0.52 96.63% | -0.80 54.28% | -0.62 22.67% | |
ev to operating cash flow | -74.43 - | -62.61 15.88% | -2.79 95.54% | -1.41 49.45% | -0.99 30.02% | |
ev to sales | ||||||
free cash flow per share | -0.05 - | -0.06 19.52% | -0.25 287.41% | -0.67 167.02% | -0.61 8.53% | |
free cash flow yield | -0.01 - | -0.02 19.52% | -0.10 536.24% | -0.55 438.42% | -0.78 42.16% | |
graham net net | 0.08 - | 0.05 30.98% | 1.39 2,430.14% | 0.28 79.63% | -0.16 158.13% | |
graham number | 0.46 - | 0.59 28.65% | 3.60 508.52% | 3.27 9.19% | 1.60 51.11% | |
income quality | 0.48 - | 0.25 48.40% | 0.38 54.97% | 0.61 61.42% | 0.73 19.32% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -247 - | -2.89K 1,069.23% | -903.47 - | -24.19 97.32% | ||
interest debt per share | 0.00 - | 0.00 80% | 0.02 - | 0.05 158.25% | ||
inventory turnover | ||||||
invested capital | 0.04 - | -0.08 301.79% | ||||
market cap | 44.21M - | 44.21M 0% | 15.36M 65.26% | 14.04M 8.62% | 10.71M 23.71% | |
net current asset value | 876K - | 609K 30.48% | 8.99M 1,375.70% | 5.29M 41.14% | -2.13M 140.34% | |
net debt to ebitda | 0.71 - | 0.25 65.35% | 1.34 439.54% | 0.25 81.35% | 0.19 22.83% | |
net income per share | -0.11 - | -0.26 130.56% | -0.40 54.59% | -0.97 143.55% | -0.83 15.03% | |
operating cash flow per share | -0.05 - | -0.06 19.42% | -0.25 288.14% | -0.66 167.50% | -0.61 8.01% | |
payables turnover | 0.07 - | |||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -1.28 - | -3.63 182.65% | -0.22 93.99% | -1.45 565.37% | -3.55 144.56% | |
revenue per share | ||||||
roe | -1.34 - | -4.29 221.18% | -0.28 93.55% | -1.99 619.29% | 6.02 402.06% | |
roic | -1.35 - | -4.38 224.54% | -0.38 91.26% | -2.04 431.44% | 8.02 493.90% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | 0.08 - | 0.06 28.21% | 1.44 2,295.42% | 0.49 66.14% | -0.14 128.13% | |
stock based compensation to revenue | ||||||
tangible asset value | 918K - | 659K 28.21% | 9.01M 1,266.62% | 5.62M 37.61% | -1.87M 133.35% | |
tangible book value per share | 0.08 - | 0.06 28.21% | 1.44 2,295.42% | 0.49 66.14% | -0.14 128.13% | |
working capital | 876K - | 609K 30.48% | 10.81M 1,675.86% | 5.66M 47.71% | -543K 109.60% |
All numbers in USD (except ratios and percentages)